Gilead Sciences, Inc. (GILD) — closed signal from November 3, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on February 1, 2026.
Predicted vs. what happened
What happened
Reached its target in 81 days.
The thesis — published November 3, 2025
After earnings, the stock fell even though the business just got a lot stronger. Profit margin jumped to 27.9% from 0.4%, and both data-driven ratings and investor mood look favorable. With the price having dropped hard and the recent average price turning up, shares could rebound toward earlier levels. Use small, staged buys, watch for heavier-than-usual buying, and stay mindful of pipeline and rival risks.
Primary drivers
- Profit margin jumped to 27.9% from 0.4%, showing a big turnaround
- Investor mood and independent scorecards both look positive
- Price fell too far recently and the recent average price is turning up
- Strong HIV and cancer drug lineup helps steady sales and future growth
How it played out
GILD: target reached in 81 days
Lyra published GILD at $119.50 on 2025-11-03 with 14% expected growth toward $135.34. The thesis pointed to margin improving to 27.9% from 0.4%, positive investor mood and independent scorecards, a recent price drop, a turning average price, and a HIV and cancer drug lineup that could steady sales and growth.
Inside the window, the stock reached the target in 81 days. It peaked at $142.20 on 2026-01-30, with a 19% gain, and ended at $141.95 on 2026-02-01. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.